☰

Brittany M. Ashlock, Ph.D. - Publications

Affiliations: 
2012 Microbiology and Immunology (Medicine) University of Miami, Coral Gables, FL 
Area:
Microbiology Biology, Oncology
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Ashlock BM, Ma Q, Issac B, Mesri EA. Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication. Plos One. 9: e87324. PMID 24489895 DOI: 10.1371/Journal.Pone.0087324  0.688
2014 Bayraktar UD, Diaz LA, Ashlock B, Toomey N, Cabral L, Bayraktar S, Pereira D, Dittmer DP, Ramos JC. Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas. Leukemia & Lymphoma. 55: 786-94. PMID 23837493 DOI: 10.3109/10428194.2013.818142  0.559
2013 Mesri EA, Cavallin LE, Ashlock BM, Leung HJ, Ma Q, Goldschmidt-Clermont PJ. Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis. Immunologic Research. 57: 159-65. PMID 24203444 DOI: 10.1007/S12026-013-8458-Z  0.597
2013 Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, Mesri EA, Lossos IS. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 122: 1233-42. PMID 23838350 DOI: 10.1182/Blood-2013-01-481713  0.706
2013 Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS, Ramos JC. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. The Journal of Clinical Investigation. 123: 2616-28. PMID 23635777 DOI: 10.1172/Jci64503  0.693
2011 Daftarian P, Chowdhury R, Ames P, Wei C, King AD, de Rivero Vaccari JP, Dillon L, Price J, Leung H, Ashlock B, Mesri E, Perez V, Züchner S, Reiser J, Lemmon V, et al. In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations. Hybridoma (2005). 30: 409-18. PMID 22008067 DOI: 10.1089/Hyb.2010.0120  0.6
2011 Bhatt S, Ashlock B, Natkunam Y, Ramos JC, Mesri E, Lossos IS. Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL), Blood. 118: 3728-3728. DOI: 10.1182/Blood.V118.21.3728.3728  0.689
2011 Bhatt S, Ashlock B, Toomey N, Mesri E, Ramos JC, Lossos IS. Synergistic Preclinical Activity of Bortezomib with Suberoylanilide Hydroxamic Acid (SAHA) in Primary Effusion Lymphoma (PEL) Blood. 118: 1650-1650. DOI: 10.1182/Blood.V118.21.1650.1650  0.711
2005 Schmidt B, Ashlock BM, Foster H, Fujimura SH, Levy JA. HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology. 343: 256-66. PMID 16278001 DOI: 10.1016/J.Virol.2005.09.059  0.315
2004 Schmidt B, Ashlock B, Neipel F, Levy JA. Potential screening assay for undetectable viruses on the basis of their capacity to induce alpha interferon production. Journal of Clinical Microbiology. 42: 4300-2. PMID 15365027 DOI: 10.1128/Jcm.42.9.4300-4302.2004  0.344
Show low-probability matches.